Bristol-Myers Squibb recently announced positive Phase III clinical trial data for its investigational drug, mezigdomide. The results showed that the combination therapy reduced the risk of disease progression or death by 52% in patients with relapsed or refractory multiple myeloma. This positive outcome not only lifted Bristol-Myers Squibb's stock price but also significantly boosted the market performance of biotech company C4 Therapeutics, Inc., which operates in the same field.

Following Bristol-Myers Squibb's announcement, shares of C4 Therapeutics, Inc. surged, hitting a 52-week high during the trading session and ultimately closing up over 19%. Market analysts believe investor optimism toward C4 Therapeutics, Inc. stems from the similarity in mechanism of action between its lead asset, cemdomide, and mezigdomide. Both belong to a class of targeted protein degradation drugs known as CELMoDs, which work by degrading the IKZF1/3 transcription factors to kill myeloma cells.

According to data from the SUCCESSOR-2 trial presented by Bristol-Myers Squibb at the 2026 American Society of Clinical Oncology annual meeting, the treatment regimen combining mezigdomide with carfilzomib and dexamethasone extended median progression-free survival to 18 months in patients, nearly doubling the 8.3 months observed in the control group. Notably, the trial enrolled a heavily pre-treated patient population, with 92.1% of patients having developed resistance to three main classes of therapy. Bristol-Myers Squibb's chief medical officer stated that these data further validate the company's targeted protein degradation platform.

Analysts noted that as a partner of Bristol-Myers Squibb, C4 Therapeutics, Inc. is accelerating the clinical development of its lead program, cemdomide. The company is currently conducting the Phase II MOMENTUM trial of cemdomide for relapsed or refractory multiple myeloma and is collaborating with Pfizer to explore combination therapies with bispecific antibodies.